Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion

Eye

Volumn 23, Issue 11, 2009, Pages 2023-2033

  Cheng, K C ^a,b   Wu, W C ^b,c   Chen, K J ^a  

^a KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Branch retinal vein occlusion; Intravitreal bevacizumab; Intravitreal triamcinolone acetonide; Macular oedema

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; TOBRAMYCIN; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; BRANCH RETINAL VEIN OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOPHTHALMITIS; EYE INFLAMMATION; EYE TOXICITY; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; INTRAOCULAR PRESSURE; MALE; MEDICAL RECORD REVIEW; MORPHOLOGY; OPTICAL COHERENCE TOMOGRAPHY; RECURRENT DISEASE; REPEAT PROCEDURE; RETINA DETACHMENT; RETINA MACULA EDEMA; RETINA MACULA LUTEA; RETROSPECTIVE STUDY; REVIEW; THICKNESS; THROMBOEMBOLISM; UVEITIS; VISION; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY;

EID: 70450199453     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.230     Document Type: Review

References (51)

1. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 1996; 114(10): 1243-1247. (Pubitemid 26338856)
2. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984; 98(3): 271-282.
3. Becker B, Post LT Jr. Retinal vein occlusion. Clinical and experimental observations. Am J Ophthalmol 1951; 34(5:1): 677-686.
4. Blankenship GW, Okun E. Retinal tributary vein occlusion. History and management by photocoagulation. Arch Ophthalmol 1973; 89(5): 363-368.
5. Gutman FA, Zegarra H. The natural course of temporal retinal branch vein occlusion. Trans Am Acad Ophthalmol Otolaryngol 1974; 78(2): OP178-OP192.
6. Christoffersen NL, Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology 1999; 106(11): 2054-2062.
7. Gutman FA, Zegarra H. Macular edema secondary to occlusion of the retinal veins. Surv Ophthalmol 1984; 28(Suppl): 462-470.
8. Finkelstein D. Ischemic macular edema. Recognition and favorable natural history in branch vein occlusion. Arch Ophthalmol 1992; 110(10): 1427-1434.
9. McAllister IL, Douglas JP, Constable IJ, Yu DY. Laserinduced chorioretinal venous anastomosis for non-ischemic central retinal vein occlusion: evaluation of the complications and their risk factors. Am J Ophthalmol 1998; 126(2): 219-229.
10. Greer DV, Constable IJ, Cooper RL. Macular oedema and retinal branch vein occlusion. Aust J Ophthalmol 1980; 8(3): 207-209.
11. Han DP, Mieler WF, Burton TC. Submacular fibrosis after photocoagulation for diabetic macular edema. Am J Ophthalmol 1992; 113(5): 513-521.
12. Striph GG, Hart WM Jr, Olk RJ. Modified grid laser photocoagulation for diabetic macular edema. The effect on the central visual field. Ophthalmology 1988; 95(12): 1673-1679.
13. Okuyama M, Okisaka S. Automatic static threshold perimetry is useful for estimating the effects of laser photocoagulation on diabetic maculopathy. Ophthalmic Res 1998; 30(4): 207-215.
14. Schatz H, Madeira D, McDonald HR, Johnson RN. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol 1991; 109(11): 1549-1551.
15. Lewis H, Schachat AP, Haimann MH, Haller JA, Quinlan P, Von Fricken MA et al. Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology 1990; 97(4): 503-510; discussion 510-1501
16. CekiçO, Chang S, Tseng JJ, Barile GR, Del Priore LV, Weissman H et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 2005; 25(7): 851-855. (Pubitemid 41456575)
17. Krepler K, Ergun E, Sacu S, Richter-Müksch S, Wagner J, Stur M et al. Intravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot study. Acta Ophthalmol Scand 2005; 83(5): 600-604. (Pubitemid 41488636)
18. Chen SD, Sundaram V, Lochhead J, Patel CK. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2006; 141(5): 876-883.
19. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007; 27(4): 419-425.
20. Gündüz K, Bakri SJ. Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Eye 2008; 22(9): 1168-1171.
21. Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008; 16(4): 791-799.
22. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001; 108(4): 765-772.
23. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109(5): 920-927.
24. Andrade RE, Muccioli C, Farah ME, Nussenblatt RB, Belfort R Jr. Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 2004; 137(3): 572-574.
25. Goff MJ, Jumper JM, Yang SS, Fu AD, Johnson RN, McDonald HR et al. Intravitreal triamcinolone acetonide treatment of macular edema associated with central retinal vein occlusion. Retina 2006; 26(8): 896-901.
26. Vinores SA, Youssri AI, Luna JD, Chen YS, Bhargave S, Vinores MA et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol 1997; 12(1): 99-109.
27. Fischer S, Renz D, Schaper W, Karliczek GF. In vitro effects of dexamethasone on hypoxia-induced hyperpermeability and expression of vascular endothelial growth factor. Eur J Pharmacol 2001; 411(3): 231-243.
28. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005; 140(2): 256-261.
29. Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2006; 244(3): 309-315.
30. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007; 143(4): 601-606.
31. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL et al. Intravitreal bevacizumab (avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006; 26(3): 279-284.
32. Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 2007; 27(8): 1004-1012.
33. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R et al. Intravitreal bevacizumab (avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26(9): 999-1005.
34. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007; 114(4): 743-750. (Pubitemid 46483714)
35. Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009; 247(1): 27-33.
36. Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 2009; 93(4): 452-456.
37. McCuen BW 2nd, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981; 91(6): 785-788.
38. Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986; 101(2): 190-195.
39. Kivilcim M, Peyman GA, El-Dessouky ES, Kazi AA, Cheema R, Hegazy H. Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic Surg Lasers 2000; 31(6): 474-478.
40. Luthra S, Narayanan R, Marques LE, Chwa M, Kim DW, Dong J et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 2006; 26(5): 512-518.
41. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26(3): 257-261.
42. Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006; 26(3): 262-269.
43. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26(3): 270-274.
44. Lee H, Shah GK. Intravitreal triamcinolone as primary treatment of cystoid macular edema secondary to branch retinal vein occlusion. Retina 2005; 25(5): 551-555.
45. Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB. Secondary ocular hypertension after intravitreal injection of 4mg of triamcinolone acetonide: incidence and risk factors. Retina 2008; 28(4): 573-580.
46. CekiçO, Chang S, Tseng JJ, Barile GR, Weissman H, Del Priore LV et al. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina 2005; 25(7): 846-850. (Pubitemid 41456574)
47. Agrawal S, Agrawal J, Agrawal TP. Conjunctival ulceration following triamcinolone injection. Am J Ophthalmol 2003; 136(3): 539-540.
48. Jonas JB, Spandau UH, Schlichtenbrede F. Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye 2008; 22(4): 590-591.
49. Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB, Martidis A. Infectious and presumed non-infectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003; 23(5): 686-691.
50. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003; 121(9): 1279-1282.
51. Yepremyan M, Wertz FD, Tivnan T, Eversman L, Marx JL. Early treatment of cystoid macular edema secondary to branch retinal vein occlusion with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging 2005; 36(1): 30-36.